Life‑sciences safety shock
Structure Therapeutics’ oral obesity pill showed up to 16.3% weight loss in a new study, while the FDA issued a formal warning that Novo Nordisk failed to report deaths tied to its GLP‑1 drugs — a pair of developments that tighten the spotlight on board‑level safety and compliance oversight in drugmakers reported and reported.
Structure reported Phase 2 ACCESS II topline showing placebo‑adjusted mean weight loss of 16.3% at 180 mg and 16.0% at 240 mg after 44 weeks for aleniglipron. (ir.structuretx.com) The company also published ACCESS open‑label extension data showing continued weight loss to 16.2% at 56 weeks on a 120 mg regimen and reported AE‑related discontinuations of 2.0–3.4% with a 2.5 mg starting dose. (ir.structuretx.com) Structure scheduled an end‑of‑Phase‑2 meeting with FDA in Q2 2026 and said Phase 3 initiation remains on track for 2H 2026, while markets moved the stock up into the double digits on the news. (ir.structuretx.com) The FDA’s formal Warning Letter to Novo Nordisk is dated March 5, 2026 and cites an inspection at the company’s Plainsboro, NJ site conducted January 13–February 7, 2025 that identified “serious violations” of PADE reporting requirements under section 505(k) and 21 CFR 314.80. (fda.gov) The agency’s letter specifically flagged Novo Nordisk’s failure to develop adequate written procedures for surveillance, receipt, evaluation and reporting of post‑marketing adverse drug experiences and documents the company’s multiple written responses submitted between March 3, 2025 and January 15, 2026. (fda.gov) Coverage of the FDA action notes the agency cited unreported serious adverse events, including multiple deaths and a suicide tied to semaglutide products, and Novo has acknowledged receiving the Warning Letter and stated it will implement corrective and preventive actions. (raps.org)
